Similar articles for PMID: 33813392

Year	Number of Results
2001	2
2004	1
2005	1
2006	3
2007	3
2008	3
2009	4
2010	3
2011	2
2012	5
2013	5
2014	3
2015	7
2016	9
2017	8
2018	9
2019	12
2020	6
2021	4
2022	1
2024	0

1

Serum Proteomic Profiling Reveals Differentially Expressed IGHG3 and A1AG1 as Potential Predictors of Chemotherapeutic Response in Advanced Non-small Cell Lung Cancer.

Mon MM, Srisomsap C, Chokchaichamnankit D, Watcharatanyatip K, Weeraphan C, Svasti J, Maneechai K, Thongsuksai P, Raungrut P. Mon MM, et al. Anticancer Res. 2021 Apr;41(4):1871-1882. doi: 10.21873/anticanres.14953. Anticancer Res. 2021. PMID: 33813392

2

The clinical significance of CXCL16 in the treatment of advanced non-small cell lung cancer.

Shibata Y, Kobayashi N, Sato T, Nakashima K, Kaneko T. Shibata Y, et al. Thorac Cancer. 2020 May;11(5):1258-1264. doi: 10.1111/1759-7714.13387. Epub 2020 Mar 12. Thorac Cancer. 2020. PMID: 32163231 Free PMC article.

3

Association between serum biomarkers CEA and LDH and response in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy.

de Jong C, Deneer VHM, Kelder JC, Ruven H, Egberts TCG, Herder GJM. de Jong C, et al. Thorac Cancer. 2020 Jul;11(7):1790-1800. doi: 10.1111/1759-7714.13449. Epub 2020 May 7. Thorac Cancer. 2020. PMID: 32383328 Free PMC article.

4

Circulating endothelial cells in non-small cell lung cancer patients treated with carboplatin and paclitaxel.

Kawaishi M, Fujiwara Y, Fukui T, Kato T, Yamada K, Ohe Y, Kunitoh H, Sekine I, Yamamoto N, Nokihara H, Watabe T, Shimoda Y, Arao T, Nishio K, Tamura T, Koizumi F. Kawaishi M, et al. J Thorac Oncol. 2009 Feb;4(2):208-13. doi: 10.1097/JTO.0b013e318193030d. J Thorac Oncol. 2009. PMID: 19179898 Free article.

5

Quality-adjusted Outcomes Stratified by Response in Patients With Advanced Non-Small-cell Lung Cancer Receiving First-line nab-Paclitaxel/Carboplatin or Paclitaxel/Carboplatin.

Hirsh V, Wan Y, Lin FJ, Margunato-Debay S, Ong TJ, Botteman M, Langer C. Hirsh V, et al. Clin Lung Cancer. 2018 Sep;19(5):401-409.e4. doi: 10.1016/j.cllc.2018.04.023. Epub 2018 May 7. Clin Lung Cancer. 2018. PMID: 29903552 Free article.

6

Safety and efficacy analysis by histology of weekly nab-paclitaxel in combination with carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer.

Socinski MA, Okamoto I, Hon JK, Hirsh V, Dakhil SR, Page RD, Orsini J, Yamamoto N, Zhang H, Renschler MF. Socinski MA, et al. Ann Oncol. 2013 Sep;24(9):2390-6. doi: 10.1093/annonc/mdt235. Epub 2013 Jul 10. Ann Oncol. 2013. PMID: 23842283 Free article. Clinical Trial.

7

The Safety and Efficacy of Treatment with Nab-paclitaxel and Carboplatin for Patients with Advanced Squamous Non-small Cell Lung Cancer Concurrent with Idiopathic Interstitial Pneumonias.

Fujita T, Hiroishi T, Shikano K, Yanagisawa A, Hayama N, Amano H, Nakamura M, Hirano S, Tabeta H, Nakamura S. Fujita T, et al. Intern Med. 2018 Jul 1;57(13):1827-1832. doi: 10.2169/internalmedicine.0404-17. Epub 2018 Feb 9. Intern Med. 2018. PMID: 29434143 Free PMC article.

8

Carboplatin plus Weekly Paclitaxel with Bevacizumab for First-line Treatment of Non-small Cell Lung Cancer.

Kubota T, Okano Y, Sakai M, Takaoka M, Tsukuda T, Anabuki K, Kawase S, Miyamoto S, Ohnishi H, Hatakeyama N, Machida H, Urata T, Yamamoto A, Ogushi F, Yokoyama A. Kubota T, et al. Anticancer Res. 2016 Jan;36(1):307-12. Anticancer Res. 2016. PMID: 26722058 Clinical Trial.

9

Prognostic Significance of Serum miR-22, miR-125b, and miR-15b in Non-Small Cell Lung Cancer Patients.

Shi GL, Zhang XY, Chen Y, Ma S, Bai WQ, Yin YJ. Shi GL, et al. Clin Lab. 2020 Jun 1;66(6). doi: 10.7754/Clin.Lab.2019.191129. Clin Lab. 2020. PMID: 32538046

10

Cetuximab plus carboplatin and paclitaxel with or without bevacizumab versus carboplatin and paclitaxel with or without bevacizumab in advanced NSCLC (SWOG S0819): a randomised, phase 3 study.

Herbst RS, Redman MW, Kim ES, Semrad TJ, Bazhenova L, Masters G, Oettel K, Guaglianone P, Reynolds C, Karnad A, Arnold SM, Varella-Garcia M, Moon J, Mack PC, Blanke CD, Hirsch FR, Kelly K, Gandara DR. Herbst RS, et al. Lancet Oncol. 2018 Jan;19(1):101-114. doi: 10.1016/S1470-2045(17)30694-0. Epub 2017 Nov 20. Lancet Oncol. 2018. PMID: 29169877 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

75 results

Results by year